Navigation Links
Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
Date:7/9/2009

Company seeks partner to commercialize the technology

TORONTO, July 9 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) announced today that it has filed key patent applications based on its novel semen sexing discoveries and that it will now embark on the path to commercialization of this exciting technology.

Microbix' recent discoveries should provide a more cost-effective platform for semen sexing and significantly improve yields and quality of the sperm produced compared to the current commercial sexing technology.

Both are critical market factors that Microbix believes will allow the company to effectively penetrate and even expand the $3 billion Artificial Insemination (AI) market.

Semen sexing is instrumental to the dairy industry due to the growing international demand for female offspring and the negligible value of dairy bull calves.

"This market is attractive for its size and the absence of regulatory barriers, and importantly, our technology offers a predictable pathway through development to market," said William J. Gastle, C.E.O.

"Now that the intellectual property has been secured, we are focused on finding a strategic partner(s) to help realize Microbix' Semen Sexing Technology's (SST) significant commercial potential and we invite expressions of interest," said Mr. Gastle.

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Mississauga.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize SST; non-adoption of SST. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. Arrow International Files and Mails Definitive Proxy Materials
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... 2017 , ... AMRI, a global contract research, development and ... outcomes and quality of life, will now be offering its impurity solutions as ... regulatory requirements for all new drug products, including the finalization of ICH M7 ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):